Evogene Ltd. (NASDAQ: EVGN) received a Nasdaq non‑compliance notice on April 2 2026 after its closing bid price stayed below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2). The exchange granted the company a 180‑day cure period that ends on September 28 2026, during which the bid price must reach at least $1.00 for ten consecutive business days to avoid delisting. A further 180‑day extension is possible if the company meets other listing standards.
The notice highlights the company’s liquidity and valuation challenges. With a market capitalization of roughly $7.75 million, Evogene’s share price is well below the $1.00 threshold, and the company’s bid price has been consistently under that level for nearly a month. The Nasdaq requirement is a strict trigger that can quickly lead to a loss of listing status and reduced access to capital markets.
Evogene’s recent financial results provide context for the low share price. In Q4 2025 the company posted a net loss of $5.4 million, compared with a $5 000 loss in the same quarter a year earlier. The full‑year 2025 loss was $7.8 million, an improvement from $18.1 million in 2024, while revenue fell to $3.9 million from $5.6 million the prior year. The decline in revenue was driven by reduced financial income and higher cost of revenues, partly due to an inventory impairment recorded by its subsidiary Casterra. Despite beating revenue estimates, the company’s earnings per share widened, reflecting the impact of the impairment and lower revenue mix.
Management has outlined a strategy to address the listing risk and improve financial performance. CEO Ofer Haviv has emphasized that maintaining the Nasdaq listing is a priority and that the company is exploring options such as a reverse stock split or a capital raise. Evogene is also concentrating on its ChemPass AI™ platform, a proprietary AI‑driven chemistry tool, and has entered a collaboration with Google Cloud to integrate AI agents into the platform. The company’s history of stock splits—including a 1‑for‑10 reverse split in July 2024—and a $5.5 million fundraising round in August 2024 demonstrate its willingness to adjust capital structure to support its strategic focus.
Analysts have expressed mixed views on Evogene’s outlook. While the company’s recent earnings beat revenue estimates, the wider EPS loss and the Nasdaq notice add uncertainty. The market is watching how quickly the company can lift its bid price and whether its AI‑centric strategy will generate sustainable revenue growth. The potential for a reverse split or additional capital raise remains a key factor in the company’s path to compliance.
The Nasdaq notice underscores a significant risk to Evogene’s continued presence on the capital market. Failure to meet the bid‑price requirement by the September 28 deadline could trigger delisting, which would severely limit liquidity and access to capital. The company’s focus on the ChemPass AI platform and its partnership with Google Cloud represent strategic initiatives that could drive future revenue, but the immediate challenge is to raise the bid price and demonstrate financial resilience. Investors will monitor the company’s progress toward compliance and its ability to execute its strategic plan to avoid delisting and restore investor confidence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.